Anxiety in medically ill patients

Current Psychiatry Reports

Volumn 8, Issue 3, 2006, Pages 228-233

  Mago, Rajnish ^a   Gomez, John Paul ^b   Gupta, Namita ^b   Kunkel, Elisabeth J S ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AMFEBUTAMONE; ANTINEOPLASTIC AGENT; ANXIOLYTIC AGENT; BACLOFEN; BENZODIAZEPINE; BETA INTERFERON; BUSPIRONE; CAPTOPRIL; CITALOPRAM; CORTICOSTEROID; DIAZEPAM; ESCITALOPRAM; ESTROGEN; FLUOXETINE; FLUVOXAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IFOSFAMIDE; LEVODOPA; LORAZEPAM; NORTRIPTYLINE; OXAZEPAM; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TEMAZEPAM; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VINBLASTINE;

ANXIETY; ANXIETY DISORDER; ARTICLE; BEHAVIOR THERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE THERAPY; DETERIORATION; DRUG HALF LIFE; GASTROINTESTINAL DISEASE; HEALTH CARE UTILIZATION; HUMAN; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PREVALENCE; PSYCHOTHERAPY; RESPIRATORY TRACT DISEASE; SEDATION; SOMNOLENCE;

ANXIETY; ANXIETY DISORDERS; CHRONIC DISEASE; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; HUMANS; PSYCHOTHERAPY; PSYCHOTROPIC DRUGS; SICK ROLE;

EID: 33745259559     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-006-0028-9     Document Type: Article

References (48)

1. Kessler RC, McGonagle KA, Zhao S, et al.: Lifetime and 12-month prevalence of the DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994, 51:8-19.
2. Sareen J, Cox BJ, Afifi TO, et al.: Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. Arch Gen Psychiatry 2005, 62:1249-1257.
3. Kessler RC, Nelson CB, McGonagle KA, et al.: The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. Am J Orthopsychiatry 1996, 66:17-31.
4. Levenson JL: Anxiety in the medically ill. Primary Psychiatry 2005, 12:24-26.
5. Sareen J, Cox BJ, Clara I, et al.: The relationship between anxiety disorders and physical disorders in the US National Comorbidity Survey. Depress Anxiety 2005, 21:193-202.
6. Regier DA, Boyd JH, Burke J, et al.: One-month prevalence of mental disorders in the United States. Arch Gen Psychiatry 1988, 45:977-986.
7. Dupont RL, Rice DP, Miller LS, et al.: Economic costs of anxiety disorders. Anxiety 1996, 2:167-172.
8. Young AS, Klap R, Sherbourne CD, Wells KB: The quality of care for depressive and anxiety disorders in the United States. Arch Gen Psychiatry 2001, 58:55-61.
9. Stein MB, Sherbourne CD, Craske MG: Quality of care for primary care patients with anxiety disorders. Am J Psychiatry 2004, 161:2230-2237.
10. Abramowicz M: Some drugs that cause psychiatric symptoms. Med Lett Drugs Ther 1998, 40:21-24.
11. Levenson JL, Hamer RM, Rossiter LF: Relation of psychopathology in general medical inpatients to use and cost of services. Am J Psychiatry 1990, 147:1498-1503.
12. Harman JS, Rollman BL, Hanusa BH, et al.: Physician office visits of adults for anxiety disorders in the United States, 1985-1998. J Gen Intern Med 2002, 17:165-172.
13. Frasure-Smith N: In-hospital syrioptoms of psychological stress as predictors of long-term outcome after acute myocardial infarction in men. Am J Cardiol 1991, 67:121-127.
14. Cossette S, Frasure-Smith N, Lesperance F: Clinical implications of a reduction in psychological distress on cardiac prognosis in patients participating in a psychosocial intervention program. Psychosom Med 2001, 63:257-266.
15. Eaker ED, Sullivan LM, Kelly-Hayes M, et al.: Tension and anxiety and the prediction of the 10-year incidence of coronary heart disease, atrial fibrillation, and total mortality: the Framingham Offspring Study. Psychosom Med 2005, 67:692-696.
16. Kawachi I, Colditz GA, Ascherio A, et al.: Prospective study of phobic anxiety and risk of coronary heart disease in men. Circulation 1994, 89:1992-1997.
17. Sola CL, Bostwick JM: implantable cardioverter-defibrillators, induced anxiety, and quality of life [review]. Mayo Clin Proc 2005, 80:232-237.
18. Brenes GA: Anxiety and chronic obstructive pulmonary disease: prevalence, impact, and treatment. Psychosom Med 2003, 65:963-970.
19. Gudmundsson G, Gislason T, Janson C, et al.: Risk factors for rehospitalisation in COPD: role of health status, anxiety and depression. Eur Respir J 2005, 26:414-419.
20. Lowe B, Grafe K, Ufer C, et al.: Anxiety and depression in patients with pulmonary hypertension. Psychosom Med 2004, 66:831-836.
21. Katon WJ, Richardson L, Lozano P, McCauley E: The relationship of asthma and anxiety disorders. Psychosom Med 2004, 66:349-355.
22. Creed F, Olden KW: Gastrointestinal disorders. In The American Psychiatric Publishing Textbook of Psychosomatic Medicine. Edited by Levenson JL. Washington, DC: American Psychiatric Publishing; 2005:465-481.
23. Drossman DA, Creed FH, Olden KW, et al.: Psychosocial aspects of the functional gastrointestinal disorders. In Rome II: The Functional Gastrointestinal Disorders, edn 2. Edited by Drossman DA, Corazziari E, Talley NH, et al. McLean, VA: Degnon; 2000:157-245.
24. Bennett EJ, Tennant CC, Piesse C, et al.: Level of chronic life stress predicts clinical outcome in irritable bowel syndrome. Gut 1998, 43:256-261.
25. Longstreth GF, Wolde-Tsadik G: Irritable bowel-type symptoms in HMO examinees. Prevalence, demographics, and clinical correlates. Dig Dis Sci 1993, 38:1581-1589.
26. Baider L, Peretz R, Hadani PE, et al.: Transmission of response to trauma? Second-generation Holocaust survivors' reaction to cancer. Am J Psychiatry 2000, 157:904-910.
27. Massie MJ, Greenberg DB: Oncology. In The American Psychiatric Publishing Textbook of Psychosomatic Medicine. Edited by Levenson JL. Washington, DC: American Psychiatric Publishing; 2005:517-534.
28. Chan CW, Richardson A, Richardson JA: Study to assess the existence of the symptom cluster of breathlessness, fatigue and anxiety in patients with advanced lung cancer. Eur J Oncol Nurs 2005, 9:325-333.
29. Stark D, Kiely M, Smith A, et al.: Anxiety disorders in cancer patients: their nature, associations, and relation to quality of life. J Clin Oncol 2002, 20:3137-3148.
30. Kadan-Lottick NS, Venderwerker LC, Block SD, et al.: Psychiatric disorders and mental health service use in patients with advanced cancer: a report from the coping with cancer study. Cancer 2005, 104:2872-2881.
31. Burvill PW, Johnson GA, Jamorozik KD, et al.: Anxiety disorders after stroke: results from the Perth Community Stroke Study. Br J Psychiatry 1995, 166:328-332.
32. Astrom M: Generalized anxiety disorder in stroke patients: a three-year longitudinal study. Stroke 1996, 27:270-275.
33. Shimoda K, Robinson RG: Effects of anxiety disorder on impairment and recovery from stroke. J Neuropsychiatry Clin Neurosci 1998, 10:34-40.
34. Menza MA, Robertson-Hoffman DE, Bonapace AS: Parkinson's disease and anxiety: comorbidity with depression. Biol Psychiatry 1993, 34:465-470.
35. Jalava M, Sillanpaa M: Concurrent illness in adults with childhood-onset epilepsy: a population-based 35-year follow-up study. Epilepsia 1996, 37:1155-1163.
36. Goddard AW, Brouette T, Almai A, et al.: Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 2001, 58:681-686.
37. Reiman, EM: Anxiety. In The Practitioner's Guide to Psychoactive Drugs, edn 4. Edited by Gelenberg AJ, Bassuk, EL. New York: Plenum; 1998:213-264.
38. Franco-Bronson K: The management of treatment-resistant depression in the medically ill. Psychiatr Clin North Am 1996, 19:329-350.
39. Argyropoulou P, Patakas D, Koukou A, et al.: Buspirone effect on breathlessness and exercise performance in patients with chronic obstructive pulmonary disease. Respiration 1993, 60:216-220.
40. Borson S, McDonald GJ, Gayle T, et al.: Improvement in mood, physical symptoms, and function with nortriptyline for depression in patients with chronic obstructive pulmonary disease. Psychosomatics 1992, 33:190-201.
41. Sheehan DV: Attaining remission in generalized anxiety disorder: venlafaxine extended release comparative data. J Clin Psychiatry 2001, 62(Suppl 19):26-31.
42. Sanderson NB, Armstrong SC, Cozza KL: An overview of psychotropic drug-drug interactions. Psychosomatics 2005, 46:464-494.
43. Ball S, Goddard A, Shekhar A: Evaluating and treating anxiety disorders in medical settings. J Postgrad Med 2002, 48:317-321.
44. Kunik ME, Braun U, Stanley MA: One session cognitive behavioural therapy for elderly patients with chronic obstructive pulmonary disease. Psychol Med 2001, 31:717-723.
45. Renfroe KL: Effect of progressive relaxation on dyspnea and state anxiety in patients with chronic obstructive pulmonary disease. Heart Lung 1988, 17:408-413.
46. Gift AG, Moore T, Soeken K: Relaxation to reduce dyspnea and anxiety in COPD patients. Nurs Res 1992, 41:242-246.
47. Vila R, Benedicto M, Pujadas C, et al.: Usefulness of relaxation techniques for patients with ischaemic cardiopathy: intervention in a health district [in Spanish]. Aten Primaria 2005, 36:78-84.
48. Spiegel D, Kiely M, Smith A, et al.: Effect of psychosocial treatment on survival of patients with metastatic breast cancer. Lancet 1989, 20:88-89.